Novotech

CBR International is a consulting firm specializing in drug development for biotechnology and pharmaceutical companies. The company provides technical consulting services in FDA representation, strategic program development, process development, and clinical program development. CBR International's team comprises scientists, engineers, clinicians, and regulatory experts who are committed to advancing scientific knowledge and fostering collaborative teamwork. By offering global product development support, clinical oversight, and strategic regulatory operations, CBR International aims to facilitate efficient and cost-effective product development for its clients.

EastHORN Clinical Services is a full-service contract research organization (CRO) that supports pharmaceutical and biotechnology companies in Europe. The organization specializes in developing treatments across various therapeutic areas, including cardiovascular diseases, dermatology, endocrinology, metabolic diseases, gastroenterology, oncology, and immunology. EastHORN offers a comprehensive range of services, including clinical monitoring, clinical project management, clinical staff provision, and regulatory services. The company is committed to delivering complex studies efficiently and cost-effectively, ensuring that drug development processes meet the needs of its clients.

NCGS, Incorporated is a global full-service clinical research organization (CRO) that offers comprehensive support for clinical development to pharmaceutical, biotechnology, medical device, and diagnostic companies. With over 30 years of experience, NCGS employs a highly skilled team dedicated to delivering studies on time, within budget, and with the highest quality standards. The organization is a WBENC-certified diversity supplier and has successfully supported the approval or expanded labeling of 34 products without receiving any 483s. NCGS emphasizes a collaborative relationship with sponsors, focusing on shared goals and trust, while addressing the complexities of the life sciences sector. The company is committed to protecting research subjects, ensuring data quality, and maintaining scientific integrity. NCGS operates across various therapeutic areas, including oncology-hematology, infectious disease, critical care, and central nervous system disorders, catering to both adult and pediatric populations. The organization aims to enhance clinical efforts by being thorough, timely, and cost-effective, guided by the principle that the products developed could impact the lives of loved ones.

Prospection Pty Ltd, established in 2009, is a Sydney-based software company specializing in healthcare data analytics. It develops SaaS platforms that transform complex healthcare data into actionable insights. Key products include PharmDash, which analyzes patient drug usage and treatment progression, and PharmMap, which integrates commercial and operational data using geospatial mapping. Prospection serves pharmaceutical companies, research institutions, and hospitals worldwide, aiding them in optimizing drug performance and enhancing patient outcomes.

ObvioHealth is a global digital health organization focused on enhancing the clinical trial process through innovative technology. The company offers a mobile clinical study application that facilitates site-less trials, enabling participants to engage in remote monitoring from their homes. This application supports continuous data collection, even between scheduled clinic visits, and fosters daily interaction through text messaging and chat features, promoting participant involvement. By connecting with various health devices such as wearables and smart health apps, ObvioHealth ensures comprehensive data gathering. Additionally, the app allows participants to schedule lab visits and manage compensation easily. The overall aim is to streamline the clinical trial process, resulting in improved data quality, increased compliance, faster recruitment, and reduced time to completion, thereby transforming the clinical research landscape.

Clinical Network Services (CNS) Pty Ltd is a Brisbane-based contract research organization specializing in the planning and execution of Phase I and II clinical trials primarily in Australia and New Zealand. Established in 1998, CNS has extensive experience in managing early-stage clinical trials, having successfully undertaken over 145 projects. The company offers a comprehensive range of services, including protocol development, study management, data management, and trial planning, which encompasses site feasibility assessments and clinical trial insurance. CNS is particularly advantageous for small to medium-sized biotech firms due to Australia’s streamlined regulatory environment, allowing for quicker proof-of-concept timelines compared to more complex processes in the United States and Europe. The firm also provides targeted services like trial manager support and bespoke product development through its "BioDesk" initiative, designed to assist clients in efficiently navigating the clinical landscape and achieving their commercial objectives. With a strong market presence, CNS has become a preferred partner for biotechnology companies looking to advance their clinical programs.